Report
Jérôme VINERIER
EUR 97.56 For Business Accounts Only

Analyse court terme - SARTORIUS STEDIM BIOTECH : Le support majeur est atteint, il cause le rebond.

La tendance est toujours haussière, son niveau d'invalidation est sous 62,23 €. L'objectif est à 78,93 €.

Arguments :
- Le support majeur est atteint, il cause le rebond.
- Les cours font un nouveau plus haut historique, ce qui témoigne de la force de la tendance.
- La moyenne mobile sert de support.
Underlying
Sartorius Stedim Biotech

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Jérôme VINERIER

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch